Junling Li

3 clinical trials · Sponsor

Record	Firm	Date
Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy (NCT04670913)	Junling Li	2021-06-28
Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy (NCT04056949)	Junling Li	2019-08-05

Every clearance here is in the API, with alerts when new ones post.